Management of Anxiety and Wandering in Lewy Body Dementia

Introduction to Management Strategies

The American Geriatrics Society recommends prioritizing non-pharmacologic interventions first, considering increasing sertraline to 100-150 mg daily if anxiety persists after behavioral strategies, adding a cholinesterase inhibitor if not already prescribed, and avoiding antipsychotics due to severe sensitivity in Lewy body dementia 1, 2

Environmental modifications are necessary for managing wandering, which is not amenable to drug therapy 3, 4, 5
The American Academy of Family Physicians suggests installing safety locks on doors and gates to prevent unsafe wandering while maintaining dignity 3, 2
Registering the patient in the Alzheimer's Association Safe Return Program immediately is recommended 3, 6, 2
Reducing environmental stimulation by minimizing glare from windows/mirrors, reducing television noise, and eliminating household clutter is advised 3, 2
Ensuring adequate lighting at night to reduce confusion and restlessness is important 3, 2

Implementing the "three R's" approach: Repeat, Reassure, and Redirect when the patient enters other residents' rooms is recommended 3, 6, 2
Establishing a predictable daily routine with consistent exercise, meals, and bedtime schedules is suggested 3, 2
Using distraction and redirection to divert attention from problematic situations is advised 3, 2
Breaking tasks into simple steps with clear, single-step instructions is recommended 3, 1

Ruling out and treating comorbid conditions that may worsen anxiety and agitation, including pain, urinary retention, constipation, and infections is necessary 3, 1, 2
Addressing sensory impairments (hearing, vision) that may contribute to behavioral symptoms is important 1

The American Family Physician recommends considering increasing sertraline gradually to 100-150 mg daily if anxiety remains the primary target symptom after non-pharmacologic interventions 3, 6
Monitoring for increased agitation during dose escalation, as SSRIs can initially worsen anxiety is advised 7

The Journal of the American Academy of Child and Adolescent Psychiatry notes that cholinesterase inhibitors have evidence for managing both cognitive and neuropsychiatric symptoms in Lewy body dementia, including anxiety and agitation 7
Starting rivastigmine at 1.5 mg twice daily with meals and increasing by 1.5 mg twice daily every 2-4 weeks as tolerated is recommended 2
Target dose for rivastigmine is 3-6 mg twice daily 2
Donepezil is an alternative with strong evidence, starting at 5 mg once daily and may increase to 10 mg daily after 4-6 weeks 2

Reassessing after 4-6 weeks to evaluate effectiveness of behavioral interventions and medication adjustments is necessary 1, 2
Attempting gradual dose reduction after behavioral symptoms are controlled for 4-6 months to determine if continued pharmacotherapy is needed is recommended 3, 5, 2
Coordinating closely with memory care staff to implement behavioral strategies consistently and monitor response is important 1